top of page
  • Active, not recruiting

NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma

Updated: Feb 10


  • NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.


INCB000928


NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.


This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.


Sponsor

 

ClinicalTrials.gov Identifier: NCT04582539

Official Title: A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

First Posted : October 9, 2020

Click here to see details on ClinicalTrials.gov

 

Drug: INCB000928

 

ALK2 Inhibitor INCB000928 (Code C175551)

ALK2 Inhibitor INCB000928

INCB 000928

INCB-000928

INCB000928

 

Locations

United States, California

United States, Florida

United States, Louisiana

United States, Michigan

United States, Ohio

United States, Tennessee

United States, Texas

Europe

France

Italy




Comments


Commenting has been turned off.
Posts Archive
bottom of page